MAOB and Parkinson disease: Furthermore, rasagiline treatment suppresses α-syn/TrkB complex formation by inhibiting the production of the MAO-B-mediated DA metabolite, 3,4-dihydroxyphenylacetaldehyde (DOPAL) in the SNpc of α-Syn- or MPTP-induced PD mouse models.